Journal article
Clinical use of therapies targeting tumor vasculature and stroma
ID Davis, J Desai
Current Cancer Drug Targets | BENTHAM SCIENCE PUBL LTD | Published : 2008
Abstract
Many recent advances in cancer therapy have been based on an understanding of the basic biology of the cancer cell itself, particularly with respect to abnormalities in various signalling pathways. It has become increasingly apparent that malignant cells exist in a complex cellular and extracellular microenvironment, which can play key roles in the initiation and maintenance of the malignant phenotype. These interactions can provide therapeutic targets that are now being exploited in the clinic. Much attention has been paid to agents that disrupt angiogenesis or existing tumor vasculature, however other cellular and non-cellular components of the tumor mass mediate critical functions and can..
View full abstractGrants
Funding Acknowledgements
IDD is supported in part by a Victorian Cancer Agency Clinician Researcher Fellowship and is an Australian NHMRC Honorary Practitioner Fellow. IDD and JD are members of the Australian Pfizer Sutent Advisory Board. IDD is also chair of the Bayer Nexavar Advisory Board and a member of the Wyeth Torisel (RCC) Advisory Board, with all payments for his work donated to the Austin Hospital Medical Research Foundation to support research into urologic cancers. JD is also member of the Novartis GIST Advisory Board, and has received speaking honoraria from Pfizer and Novartis.